# Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

> **NCT05861453** · PHASE2 · COMPLETED · sponsor: **Afimmune** · enrollment: 35 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Epeleuton

## Key facts

- **NCT ID:** NCT05861453
- **Lead sponsor:** Afimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-10
- **Primary completion:** 2026-01-21
- **Final completion:** 2026-02-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861453, "Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05861453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*